Instruction for use: Emoxypine solution for injections 1%

Dosage form: solution for injection

Active substance: Methylaethylpiridinolum

ATX

C05CX Drugs that reduce the permeability of capillaries, others

Pharmacological group

Antiaggregants

Antihypoxants and antioxidants

Angioprotectors and microcirculatory correctors

The nosological classification (ICD-10)

H11.3 Conjunctival hemorrhage: Hemorrhages in the eye

H30 Chorioretinal inflammation: Retinitis; Chorioretinitis; Central and peripheral chorioretinal dystrophy

H34 Vascular occlusion of retina: Arterial thrombosis of the vessels of the eye; Venous thrombosis of the vessels of the eye; Violation of retinal circulation; Disturbances of intraocular circulation; Insufficient blood supply to the mesh and choroid; Occlusion of central retinal vessels; Acute obstruction of retinal arteries; Subacute and chronic circulatory insufficiency in the retina or in the choroid of the eye; Vascular diseases of the retina; Vascular disorders in the retina of the eye; Vascular thrombosis of the retina; Central retinal vein thrombosis; Thrombosis of the central vein of the retina and its branches; Thrombosis of the central vein of the retina of the eye and its branches

H35 Other retinal disease: retinal degeneration; Retinal degenerative changes in the eye; Subacute and chronic insufficiency of blood circulation in the retina or choroid

H35.3 Macular and posterior pole degeneration: Macular degeneration; Retinal dystrophy; Angiosclerotic maculodystrophy; Age-related macular degeneration; Age-related macular degeneration; Nontranssudative forms of macular degeneration; Degenerative changes of a yellow stain; Stargardt's disease; Degenerative processes in the yellow spot; Retinal degeneration; Macular degeneration; Pigmented degeneration of the retina; Macular degeneration age (senile); Dystrophy of the mesh membrane; Hereditary pigmentary degeneration of the retina; Hereditary taperoteretal degenerations; Older macular degeneration

H35.6 Retinal hemorrhage: Hemorrhagic retinopathy; Hemorrhage in the retina; Hemorrhage in the retina of the eye; Repeated haemorrhage in the retina; Rota company; Hemorrhages in the eye; Hemorrhages in the retina at altitudes

H40 Glaucoma: glaucoma intervention; Afakicheskaya glaucoma; narrow-angle glaucoma; Chronic glaucoma; Chronic open-angle glaucoma; Wide-angle glaucoma

H43.1 Haemorrhage in the vitreous: Intraocular hemorrhage; Post-traumatic hemorrhage

H52.1 Myopia: Nearsightedness; Myopia; Complicated myopia; Myopic chorioretinitis; Progressing myopia; Complicated high degree myopia

I61 Intracerebral bleeding: apoplectic shock; Apoplexy of the brain; Hematoma subduralnoy; Hematoma epidural; Hemorrhagic stroke; Stroke apoplexy; Hemorrhagic stroke; Hemorrhage in the brain; Intra cerebral hemorrhage; Intra cerebral hemorrhage; Postponed hemorrhagic stroke; Subdural hematoma chronic; Epidural hematomas

I63 Cerebral infarction: ischemic Stroke; Ischemic brain disease; Ischemic stroke; Ischemic stroke and its consequences; Ischemic cerebral stroke; Ischemic cerebrovascular accident; Ischemic brain damage; Ischemic brain damage; ischemic conditions; Cerebral ischemia; Acute hypoxia brain; Acute cerebral ischemia; Acute ischemic cerebrovascular accident; Acute cerebral infarction; Acute ischemic stroke; Acute period of ischemic stroke; Focal cerebral ischemia; Ischemic stroke; recurrent stroke; The syndrome of Morgagni-Adams-Stokes; Chronic cerebral ischemia; cerebrovascular stroke; embolic stroke; Ischemic brain damage

L57.0 Actinic [photochemical] keratosis: Actinokeratosis; Keratosis; Keratoma

S05 Injury of the eye and orbit: Wounds of the eye penetrating; Non-penetrating wound of the eyeball; Superficial injury of the cornea; Post-traumatic keratopathy; Post-traumatic central retinal dystrophy; Penetrating wound of the cornea; Condition after eye injuries; Condition after eyeball injuries; Condition after eyeball injury; Penetrating corneal wounds; Injuries to eye tissues; Injuries to eye tissues; Injuries to the cornea; Injury of anterior part of eye

T26 Thermal and chemical burns, limited to the eye area and its adnexa: Condition after thermal conjunctival burns; Condition after thermal burns of the cornea; Aseptic eye burn; Eye Burn; Thermal eye burns; Thermal damage to the cornea; Corneal burn; Irradiated eye burn; Chemical eye burn; Chemical burn of the cornea; Chemical damage of the cornea; Thermal burns of the conjunctiva; Thermal burns of the cornea; Thermal eye burn; Condition after surgical burns of conjunctiva; Condition after surgical burns of the cornea

Composition and release form

1 ampoule with 1 ml injection solution contains emoxipine 0.01 g; In a cardboard box 10 pcs.

Pharmacology

Mode of action - Antiaggregational, angioprotective, antihypoxic.

Reduces vascular permeability and blood viscosity, normalizes tissue metabolism, incl. With stroke and heart attack.

Indications for Emoxypine solution for injections 1%

Intraocular hemorrhages, diabetic retinopathy, central chorioretinal dystrophies, central vein vein thrombosis and its branches, posttraumatic hemorrhages, complicated myopia, to protect the retina of the eye under the influence of high-intensity light (laser and solar burns, laser coagulation), in the postoperative period in patients with glaucoma Stratification of the choroid, and cerebrovascular disorders of ischemic and hemorrhagic nature (in adults).

Contraindications for Emoxypine solution for injections 1%

Hypersensitivity, pregnancy.

Side effects

Excitation (short-term), drowsiness, increased blood pressure, rash, local reactions: pain, burning sensation, itching, redness, denser parorbital tissues.

Dosage and Administration

In ophthalmology - retrobulbarno in a dose of 0.5 ml of 1% solution once a day daily for 10-15 days; Subconjunctivally and parabulbar - 0.2-0.5 ml of 1% solution once a day daily for 10-30 days (if necessary, treatment can be repeated 2-3 times a year). To protect the retina of the eye during laser coagulation, before the limiting and destructive coagulation of tumors, 0.5 ml of 1% solution is injected retrobulbarno in 24 hours and 1 hour prior to coagulation. Then apply for 2-10 days 1 time per day retrobulbarno in the same doses (0.5 ml of 1% solution). In neurology - in / m at a dose of 0.03-0.05 g (3-5 ml of 1% solution) daily 2-3 times a day for 10-30 days; With iv introduction before use, the drug is diluted in 100-200 ml of isotonic sodium chloride solution and injected dropwise (20-30 drops per minute) at a dose of 0.05-0.15 g (5-15 ml of 1% solution) 1 time Per day daily for 7-10 days (if necessary, up to 2 weeks).

Precautionary measures

It is necessary to constantly monitor blood pressure and blood clotting. Do not mix with other drugs (in one syringe).

Storage conditions of Emoxypine solution for injections 1%

In the dark place.

Keep out of the reach of children.

Shelf life

3 years

Do not use beyond the expiration date printed on the package.